Modermælkserstatning med lavt niveau af arsen

• Main Authors: Pierre CHASSAGNE, Nikolay KHANZHIN
• Format: Patent
• Language: Danish; English
• Published: 23.01.2024
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; DERIVATIVES THEREOF; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; FOODS OR FOODSTUFFS; FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J; HUMAN NECESSITIES; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; NUCLEIC ACIDS; NUCLEOSIDES; NUCLEOTIDES; ORGANIC CHEMISTRY; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL; SPIRITS; SUGARS; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES; VINEGAR; WINE

Modermælkserstatninger med et meget lavt niveau af arsen opnås ved meget omhyggelig udvælgelse af bestanddelene i modermælkserstatningen. Til fremstilling af modermælkserstatninger, der omfatter under 95 milliardtedele (ppb) arsen, foretrækkes anvendelse af humane mælkeoligosakkarider (HMO'er), der er blevet isoleret fra et fermenteringsmedium uden anvendelse af aktivt kul i det sidste oprensningstrin. Det foretrukne HMO er 2'-O-fukosyllaktose. Infant formulae with a very low level of arsenic are obtained by selecting the components of the infant formula very carefully. For manufacturing infant formulae that comprise less than 95 parts per billion (ppb) of arsenic, it is preferred to use human milk oligosaccharides (HMOs) that have been isolated from a fermentation brth without using activated carbon in the last purification step. The preferred HMO is 2′-O-fucosyllactose.